KCHC Annual Review 2023-24 WEB Singles - Flipbook - Page 52
Notes to the financial statements
2022/23 comparatives
As
restated at
31 March
Transfers
2023
At
1 April 2022
Income
Expenditure
Gains/
(Losses)
£’000
£’000
£’000
£’000
£’000
£’000
-
100
-
-
-
100
Cancer Treatment and Research
248
-
-
-
(248)
-
Paediatric Liver Laboratories
290
55
-
-
-
345
2,474
-
-
-
(165)
2,309
267
35
(113)
-
-
189
Renal legacy - Spratt
-
571
-
-
-
571
Paediatric palliative care CNS True
Colours
-
60
(120)
-
-
(60)
Robot assisted surgical system
-
-
(1,000)
-
1,000
-
197
81
(12)
-
210
476
3,476
802
(1,245)
-
797
3,830
9,746
990
(988)
-
(777)
8,971
-
-
-
-
-
-
Fund for strategic purpose
6,903
-
-
-
(3,403)
3,500
Development of capital projects
1,000
-
-
-
-
1,000
33
-
-
-
-
33
17,682
990
(988)
-
(4,180)
13,504
6,007
1,813
(3,326)
(2,320)
3,383
5,557
Total unrestricted funds
23,689
2,803
(4,314)
(2,320)
(797)
19,061
Total funds (as restated)
27,165
3,705
(5,559)
(2,320)
-
22,991
Permanent endowment funds
Restricted funds
David Hughes Special Trust
Transforming Liver Care (TLC) appeal
Other funds less than £100K
Total restricted funds
Unrestricted funds
Designated
Clinical funds
Social investment
Office fixtures and fittings
Total designated funds
General funds
Transfers include an internal allocation to each
designated and restricted fund equivalent to interest
52
S U P P O R T K I N G S .O R G .U K
earned based on the average value of the fund during
the year.
